Compare HVT & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HVT | RZLT |
|---|---|---|
| Founded | 1885 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.8M | 352.1M |
| IPO Year | 1994 | 2011 |
| Metric | HVT | RZLT |
|---|---|---|
| Price | $26.16 | $4.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | ★ $31.50 | $10.10 |
| AVG Volume (30 Days) | 102.0K | ★ 1.3M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.04% | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $758,995,000.00 | N/A |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $7.91 | N/A |
| P/E Ratio | $34.08 | ★ N/A |
| Revenue Growth | ★ 4.99 | N/A |
| 52 Week Low | $20.10 | $1.07 |
| 52 Week High | $30.60 | $11.17 |
| Indicator | HVT | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 37.57 | 52.26 |
| Support Level | $24.22 | $3.58 |
| Resistance Level | $26.87 | $5.43 |
| Average True Range (ATR) | 1.32 | 0.30 |
| MACD | -0.44 | 0.01 |
| Stochastic Oscillator | 14.49 | 69.74 |
Haverty Furniture Companies Inc is a specialty retailer of residential furniture and accessories. It provides various products such as Sofa Tables, Sleepers, End Tables, Cocktail Tables, Accent Pieces, Display Cabinets, Wall Decor, floral and Tress, and other related products. The company operates in the Southern and Midwestern U.S. All its activities are encompassed in its Merchandise division. The company derives the majority of revenue from its upholstery products and, secondarily, from bedroom furniture.
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.